



ASX ANNOUNCEMENT

2 May 2024

## **Dr Rebecca McQualter appointed COO**

- **Senior experience in big pharma roles at Novartis, Amgen & GSK**
- **Doctor of Philosophy in Cell Therapy & Regenerative Medicine from Monash University**
- **Strong capability in developing commercial partnerships & networks with various stakeholders**
- **Senior leadership role as second employee in startup Bioverativ – built multi-million sales from scratch in one year before the company was acquired**

**Sydney, Australia, 2 May 2024:** Chimeric Therapeutics (ASX:CHM, “Chimeric” or the “Company”), an Australian leader in cell therapy, is pleased to announce the appointment of Rebecca McQualter, PhD, to the position of Chief Operating Officer (COO) based in Melbourne.

Dr McQualter will bring senior experience from roles at Novartis, Amgen and GlaxoSmithKline. Dr McQualter holds a Doctor of Philosophy in Cell Therapy and Regenerative Medicine from Monash University.

Dr McQualter has an extensive commercial career with exposure to many aspects of international pharmaceutical operations. Mostly recently, as the Head of Strategic Access at Novartis Australia, Dr McQualter developed new commercial partnerships, built external networks spanning policy makers, research institutes and NGOs, and engaged with federal and state government, trade associations and other stakeholders to implement policy and process improvements. She led the establishment of key partnerships for Novartis with Telstra Health, Monash University and Wesfarmers Health.

Prior to her role at Novartis, Dr McQualter was Country Medical Head for Bioverativ ANZ, a \$5 billion Biogen spinout focusing on rare diseases. She played a key role in establishing business processes and strategies, setting up medical information/pharmacovigilance call centres, and conducting payer negotiations, aiding in Bioverativ's multi-billion-dollar acquisition by Sanofi in 2018.

She has also previously held leadership roles at Amgen, where she initially worked in Australia before moving to the United States to take on the role of Senior Marketing Manager for Strategic Operations in Oncology at Amgen's Thousand Oaks, California office. Further big pharma experience came at GlaxoSmithKline, where Dr McQualter worked as a Medical Adviser and learning from the ground up as a Primary Care Sales Representative, where she contributed to launching two major brands.

Executive Chairman, Paul Hopper, said: "We're very fortunate to be welcoming Rebecca to Chimeric as we continue to grow and advance our portfolio of transformative cell therapies. She brings an



excellent array of experience, including having worked alongside Amgen's Global Head of Oncology in the US, as well as a commercial focus and dynamic leadership skills that will serve Chimeric well as it pursues its next phase of growth."

Dr McQualter will receive annual fixed cash remuneration of A\$300,000, with variable remuneration incentive of up to 40% of the fixed remuneration based on achievement of key performance indicators agreed to with the Board of Directors. In addition, Dr McQualter will receive 20 million options in the Company, vesting annually over a four-year period.

Authorised on behalf of the Chimeric Therapeutics board of directors by Chairman Paul Hopper.

## **ABOUT CHIMERIC THERAPEUTICS**

Chimeric Therapeutics, a clinical stage cell therapy company and an Australian leader in cell therapy, is focused on bringing the promise of cell therapy to life for more patients with cancer. We believe that cellular therapies have the promise to cure cancer, not just delay disease progression.

To bring that promise to life for more patients, Chimeric's world class team of cell therapy pioneers and experts is focused on the discovery, development, and commercialization of the most innovative and promising cell therapies.

Chimeric currently has a diversified portfolio that includes first in class autologous CAR T cell therapies and best in class allogeneic NK cell therapies. Chimeric assets are being developed across multiple different disease areas in oncology with 3 current clinical programs and plans to open additional clinical programs in 2024.

CHM 1101 (CLTX CAR T) is a novel and promising CAR T therapy developed for the treatment of patients with solid tumours. CHM 1101 is currently being studied in a phase 1B clinical trial in recurrent / progressive glioblastoma. Positive preliminary data from the investigator-initiated phase 1A trial in glioblastoma was announced in October 2023.

CHM 2101 (CDH17 CAR T) is a first-in-class, 3rd generation CDH17 CAR T invented at the world-renowned cell therapy centre, the University of Pennsylvania. Preclinical evidence for CHM 2101 was published in March 2022 in Nature Cancer demonstrating complete eradication of tumours in 7 types of cancer. CHM 2101 (CDH17 CAR T) is currently in preclinical development with a planned phase 1A clinical trial in gastrointestinal and neuroendocrine tumours.

CHM 0201 (CORE-NK platform) is a potentially best-in-class, clinically validated NK cell platform. Data from the complete phase 1A clinical trial was published in March 2022, demonstrating safety and efficacy in blood cancers and solid tumours. Based on the promising activity signal demonstrated in that trial, two additional Phase 1B clinical trials investigating CHM 0201 in combination regimens have been initiated. From the CHM 0201 platform, Chimeric has initiated development of new next generation NK and CAR NK assets.



## CONTACT

### Investors

Paul Hopper

Executive Chairman

Chimeric Therapeutics

T: + 61 406 671 515

E: [paulhopper@lifescienceportfolio.com](mailto:paulhopper@lifescienceportfolio.com)

W: [www.chimerictherapeutics.com](http://www.chimerictherapeutics.com)

### Media

Matthew Wright

NWR Communications

P: +61 451 896 420

E: [matt@nwrcommunications.com.au](mailto:matt@nwrcommunications.com.au)